A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

November 4, 2013

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
BEHAVIORAL

The risk assessment questionnaire

OTHER

Blood specimens

OTHER

tumor tissue samples will be requested

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, East White Plains

11553

Memorial Sloan Kettering Nassau, Uniondale

11724

Cold Springs Harbor Laboratory (Specimen Analysis), Cold Spring Harbor

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Weill Cornell Medical College (Specimen Analysis), New York

Shaare Zedek Medical Center, Jerusalem

Weizmann Institute of Science (Specimen Analysis), Rehovot

Sheba Medical Center, Tel Litwinsky

19104-4283

Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia

All Listed Sponsors
collaborator

Abramson Cancer Center at Penn Medicine

OTHER

collaborator

Shaare Zedek Medical Center

OTHER

collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01983410 - A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter